Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 6/20 | 0.59 |
| ▸ | HTR2A | P28223 | 6/20 | 0.59 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8597350 | 0.86 | HRH1 (0.56) | HRH1HTR2AIDO1TAAR1KCNH2 | |
| Hydrochloric Acid SCHEMBL7676546 | 0.84 | HRH1 (0.54) | HRH1HTR2AIDO1TAAR1KCNH2 | |
| SCHEMBL7784138 | 0.82 | HRH1 (0.58) | HRH1HTR2ASIGMAR1TAAR1CYP19A1 | |
| SCHEMBL7799318 | 0.78 | HRH1 (0.54) | HRH1HTR2ASIGMAR1TAAR1GRM2 | |
| SCHEMBL3959644 | 0.78 | HRH1 (0.54) | HRH1HTR2ASIGMAR1TAAR1GRM2 | |
| SCHEMBL704990 | 0.78 | HRH1 (0.54) | HRH1HTR2ASIGMAR1TAAR1GRM2 | |
| SCHEMBL9073997 | 0.78 | HRH1 (0.71) | HRH1HTR2ASIGMAR1TAAR1CYP19A1 | |
| SCHEMBL14160145 | 0.77 | HTR2A (0.53) | HRH1HTR2ASIGMAR1KCNH2 | |
| SCHEMBL6829827 | 0.77 | HRH1 (0.52) | HRH1HTR2ASIGMAR1TAAR1GRM2 | |
| SCHEMBL31505720 | 0.75 | LMNA (0.59) | HRH1HTR2AGRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | disclosed |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2017-03-16 | — | — | US | disclosed |
| US-9498489-B2 | Antimetabolite agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-8716346-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140066464-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| US-8324282-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | GERSON STANTON L (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100267657-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | CASE WESTERN RESERVE UNIVERSITY | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267657-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | HRH1 4047/4885HTR2A 4733/4885IDO1 2814/4885 |
| US-20140066464-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | UNG, NTPCR, GUSB | HRH1 4432/4885HTR2A 4348/4885IDO1 2941/4885 |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNG, TOP2A, OGG1 | HRH1 3985/4885HTR2A 4776/4885IDO1 4025/4885 |
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | UNG, TP53, OGG1 | HRH1 4103/4885HTR2A 4488/4885IDO1 3106/4885 |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | HRH1 4047/4885HTR2A 4733/4885IDO1 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.